Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Gilead Sciences (GILD ... prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...

They grew it in an Israeli greenhouse, and it is now a 10-foot tree that produces a clear resin researchers say could be the biblical “balm of Gilead ... past decade. There is now roughly ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

In Chandler's absence, Assistant Chief Holly Murchland will serve as interim head of the division, Beidleman said, and added that there have been no permanent ... officer since 1994 when he joined the ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare ... launching a growth effort in 2019, but there has been a fair amount of turnover ...

Brian Heath has joined Gilead Sciences’ cell therapy subsidiary ... “CAR T-cell therapy has changed the paradigm of cancer treatment, and there has never been a more exciting time for cell ...